Oryzon Genomics - KOL event puts near-term catalysts in the spotlight
At Oryzon’s recent key opinion leader (KOL) event, management elaborated on the near-term clinical catalysts for its lead assets iadademstat, in oncology, and vafidemstat, in central nervous system (CNS) indications. Following the positive results of the ALICE trial, the company is fast approaching the initiation of the Phase Ib FRIDA study for iadademstat in FLT3+ relapsed/refractory (r/r) acute myeloid leukaemia (AML) patients. Management believes the r/r AML setting may represent a faster route to market for iadademstat, targeting a patient population with currently limited and sub-optimal treatment options. Management originally guided for FRIDA to be initiated by end-2022; however, this delay has been attributed to slower-than-expected trial site activation. Management has communicated that trial site activation is now progressing and that FRIDA could begin imminently. Additionally, interim data analysis from the PORTICO study in borderline personality disorder (BPD) in Q123 represents a significant catalyst for vafidemstat in the company’s leading CNS programme.Oryzon Genomics SA is a Spain-based biopharmaceutical company. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases. The Company's business model focuses on identifying biomarkers that can be translated in new therapeutic targets, as well as on investing in programs, mainly through the development of small molecules for two main indications: cancer and neurodegeneration. The Company develops investigational medicines till proof of concept (POC) phase and then partners the program with pharmaceutical entities, which are able to get the approval from drug agencies to bring these medicines to the patients. It cooperates with Roche. The Company is a subsidiary of Laboratorio Reig Jofre SA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.